Global X Genomics Etf Working Capital
| GNOM Etf | USD 10.08 0.25 2.54% |
Global X Genomics fundamentals help investors to digest information that contributes to Global X's financial success or failures. It also enables traders to predict the movement of Global Etf. The fundamental analysis module provides a way to measure Global X's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Global X etf.
Global |
Global X Genomics ETF Working Capital Analysis
Global X's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Global X Working Capital | 67.28 M |
Most of Global X's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Global X Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
According to the company's disclosures, Global X Genomics has a Working Capital of 67.28 M. This is much higher than that of the Global X Funds family and significantly higher than that of the Health category. The working capital for all United States etfs is notably lower than that of the firm.
Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Fund Asset Allocation for Global X
The fund invests 99.96% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Global X's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Global Fundamentals
| Return On Asset | -0.41 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (3.35) % | |||
| Current Valuation | 55.88 M | |||
| Shares Outstanding | 30.18 M | |||
| Shares Owned By Insiders | 35.87 % | |||
| Shares Owned By Institutions | 22.90 % | |||
| Number Of Shares Shorted | 312.41 K | |||
| Price To Earning | (1.22) X | |||
| Price To Book | 3.31 X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 19.34 M | |||
| Gross Profit | (8.96 M) | |||
| EBITDA | (57.9 M) | |||
| Net Income | (72.35 M) | |||
| Cash And Equivalents | 77.07 M | |||
| Cash Per Share | 1.01 X | |||
| Total Debt | 23.26 M | |||
| Debt To Equity | 0.78 % | |||
| Current Ratio | 1.06 X | |||
| Cash Flow From Operations | (50.51 M) | |||
| Short Ratio | 0.20 X | |||
| Earnings Per Share | (2.35) X | |||
| Number Of Employees | 255 | |||
| Beta | 1.28 | |||
| Market Capitalization | 97.23 M | |||
| Total Asset | 205.13 M | |||
| Retained Earnings | (211.2 M) | |||
| Working Capital | 67.28 M | |||
| Current Asset | 95.17 M | |||
| Current Liabilities | 27.89 M | |||
| One Year Return | (3.50) % | |||
| Three Year Return | (21.60) % | |||
| Five Year Return | (7.00) % | |||
| Net Asset | 205.13 M | |||
| Equity Positions Weight | 99.96 % |
About Global X Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Global X Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Global X using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Global X Genomics based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Global X Piotroski F Score and Global X Altman Z Score analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
The market value of Global X Genomics is measured differently than its book value, which is the value of Global that is recorded on the company's balance sheet. Investors also form their own opinion of Global X's value that differs from its market value or its book value, called intrinsic value, which is Global X's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Global X's market value can be influenced by many factors that don't directly affect Global X's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Global X's value and its price as these two are different measures arrived at by different means. Investors typically determine if Global X is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Global X's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.